OTIC Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Otonomy, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
OTIC Community Narratives
There are no narratives available yet.
Otonomy, Inc. Key Details
Last Reported Earnings
Sep 30, 2022
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.76
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 75.4%
Otonomy, Inc. Competitors
Snowflake Analysis
About OTIC
- Founded
- 2008
- Employees
- 51
- CEO
- WebsiteView website
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
The market is up 1.1% over the last week, with the Information Technology sector leading the way, up 1.9%. In the last year, the market has climbed 19%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›